SpyGlass Pharma, Inc. (SGP)
| Market Cap | 782.52M |
| Revenue (ttm) | n/a |
| Net Income | -39.87M |
| EPS | -17.98 |
| Shares Out | 33.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,481 |
| Open | 25.77 |
| Previous Close | 25.39 |
| Day's Range | 23.40 - 25.77 |
| 52-Week Range | 20.15 - 32.44 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 45.00 (+92.23%) |
| Earnings Date | Jun 24, 2026 |
About SGP
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SGP stock is "Strong Buy." The 12-month stock price target is $45.0, which is an increase of 92.23% from the latest price.
News
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business hig...
SpyGlass Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Yi Chen initiated coverage of SpyGlass Pharma (SGP) with a Buy rating and $37 price target SpyGlass is a clinical-stage biopharmaceutical company focused on the development of
SpyGlass Pharma announces results from Phase 1/2 trial of BIM-IOL System
SpyGlass Pharma (SGP) announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System, BIM-IOL System, for the treatment of elev...
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced positive 12-month results from th...
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced that members of the executive m...
3 Macro Charts That Matter Now: U.S. Dollar, Gold, S&P 500
Middle East tensions are wreaking havoc, with traditional safe havens not providing much protection.
SpyGlass Pharma initiated with an Outperform at Leerink
Leerink initiated coverage of SpyGlass Pharma (SGP) with an Outperform rating and $42 price target The firm says the company’s lead asset, the BIM-IOL-System, addresses a large market opportunity, as
SpyGlass Pharma initiated with a Buy at Jefferies
Jefferies analyst Dennis Ding initiated coverage of SpyGlass Pharma (SGP) with a Buy rating and $62 price target SpyGlass is developing a “compelling” long-acting drug release platform for the eye,
SpyGlass Pharma initiated with a Buy at Citi
Citi initiated coverage of SpyGlass Pharma (SGP) with a Buy rating and $42 price target The firm sees a positive risk/reward despite the stock’s 70% rally since the initial public
SpyGlass Pharma initiated with a Buy at Stifel
Stifel initiated coverage of SpyGlass Pharma (SGP) with a Buy rating and $42 price target The firm says that by combining a known drug, a known procedure, and a known
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial publi...
SpyGlass Pharma opens at $24.00, IPO priced at $16.00
pyGlass Pharma priced 9.375M shares $16.00, the midpoint of the $15.00-$17.00 range. Jefferies, Leerink, Citi and Stifel are acting as joint book running managers for the offering. SpyGlass Pharma (SG...
SpyGlass Pharma indicated to open at $30, IPO priced at $16
SpyGlass Pharma (SGP) priced 9.375M shares $16.00, the midpoint of the $15.00-$17.00 range. Jefferies, Leerink, Citi and Stifel are acting as joint book running managers for the offering. SpyGlass Pha...
SpyGlass Pharma Announces Pricing of Initial Public Offering
ALISO VIEJO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial publi...
SpyGlass Pharma files 9.375M share IPO, expects to price between $15.00-$17.00
SpyGlass Pharma (SGP) has filed an initial public offering of 9.375M shares of its common stock. SpyGlass currently expects that the initial public offering price will be between $15.00-$17.00 per
SpyGlass Pharma, Sustained-Release Ophthalmic Drug-Delivery Company, Files for Nasdaq Global Select Market IPO
SpyGlass Pharma filed for an initial public offering on the Nasdaq Global Select Market under the ticker SGP. The late-stage biopharmaceutical company is developing sustained-release drug-delivery sys...
SpyGlass Pharma IPO Registration Document (S-1)
SpyGlass Pharma has filed to go public with an IPO on the NASDAQ
Chronic eye condition biotech SpyGlass Pharma files for a $100 million IPO
SpyGlass Pharma, a phase 3 biotech developing implants to treat chronic eye conditions, filed on Friday with the SEC to raise up to $100 million in an initial public offering.